BriaCell Therapeutics Corp BCTX 深 沪
已收盘 08-07 16:00:00 美东时间
3.64
+0.190
+5.51%
华盛通- 最 高3.68
- 今 开3.53
- 成交量 15.36万股
- 最 低 3.46
- 昨 收 3.45
- 总市值 3166.72万
- 52周最高 14.68
- 市盈率 静 --
- 换手率 1.77%
- 52周最低 2.60
- 委 比 -52.69%
- 总股本 869.98万
- 历史最高 1860.5799
- 量 比 0.99
- 振 幅 6.38%
- 历史最低 2.60
- 每 手 1
- 风险率 3.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell’s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designe...
08-05 19:33
BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phase 3 Clinical Development And Potential Future Commercial Supply Of Its Allogenic Cell Therapy BRIA-IMT
Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). "Securing manufacturing capacity with Fujifilm, a global leader in cell therapy ...
07-15 19:35
BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMT
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (NASDAQ:CRAI) and Kaleio, Inc. to support co...
07-07 19:32
BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMT
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has entered into a Memorandum of Understanding ("MoU"), with Uneedle, a microneedle based drug-delivery device ...
06-25 19:40
BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY
BriaCell Therapeutics (NASDAQ:BCTX) reported quarterly losses of $(0.99) per share. This is a 93.96 percent increase over losses of $(16.40) per share from the same period last year.
06-10 06:08
Reported Earlier, Cancer Drug Developer BriaCell Prices $4.7M Stock Offering Of 1.45M Shares At $3.25/Share to Fund Operations and Research
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the
06-01 15:51
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Therapeutics Corp. announced the pricing of a best-efforts offering of 1,449,300 common shares at $3.25 per share, expected to raise approximately $4.7 million. Proceeds will be used for working capital, general corporate purposes, and advancing business objectives. The offering is set to close on June 2, 2026, and is being managed by ThinkEquity as the sole placement agent. The securities are being offered under a shelf registration sta...
05-31 23:59
BriaCell Therapeutics Presents Positive Clinical Data From Three Clinical Data Poster Presentations, Three Publication-Only Abstracts At 2026 ASCO Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce positive
05-22 19:31
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
BriaCell Therapeutics announced positive clinical data from three poster presentations and three abstracts at the 2026 ASCO Annual Meeting. Key findings include a median overall survival (OS) of 16.6 months for the Phase 3 Bria-IMT formulation, positive quality of life (QOL) data in heavily pretreated metastatic breast cancer (MBC) patients, and biomarker analyses confirming predictors of anti-cancer response. The Phase 2 study showed tolerable s...
05-22 11:30
BriaCell Therapeutics Completes Manufacturing Clinical Supplies Of Bria-PROS+ For Prostate Cancer
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed
05-14 19:39
